Moreover imatinib, which targets the same receptors as axitinib, except the VEGFRs, reduced the phosphorylation of c-Kit and PDGFRβ but did not inhibit myxoid liposarcoma cell proliferation/survival at a biologically relevant dose. The gene discussed is KIT; the disease is myxoid liposarcoma.